Summary
Single intransal applications of MTP-PE, a lipophilic muramyl peptide, induce tumouricidal and tumouristatic leucocytes in the lungs of rats. In ex vivo assays the tumouristatic activity was detectable for 8 days after drug administration. By separation of the effector cells on Ficoll-Hypaque gradients, it was shown that both neutrophils and macrophages are responsible for this activity. Using the B16/BL6 melanoma system in mice, there was a high survival rate after repeated intranasal applications of MTP-PE
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dietrich FM, Lukas B, Schmidtruppin KH (1983) Prophylactic and therapeutic effects of MTP-PE, a synthetic muramyl peptide in experimental virus infections. Proc of 13th Int Congress of Chemotherapy 91:50
Fidler IJ (1981) The in situ induction of tumouricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127:1719
Fidler IJ, Poste G (1981) Activation of tumouricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastases. In: GP Murphy et al. (eds) Progress in clinical and biological research Vol 75. The prostatic cell: structure and function, part B, AR Liss, New York p 257
Fidler IJ, Poste G (1982) Macrophage-mediated destruction of malignant tumour cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 5:161
Fidler IJ, Raz A, Fogler WE, Kirsch R, Bugelski P, Poste G (1980) Design of liposomes to improve delivery of macrophage-augmenting agents to alveloar macrophages. Cancer Res 40:4460
Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680
Fidler IJ, Barnes Z, Fogler WE, Kursch R, Bugelski P, Poste G (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496
Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RH, Schroit AJ (1982) Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod 1:43
Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ (1983) Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. In: JW Hadden et al. (eds) Advances in immunopharmacology. 2. Pergamon Press, London p 235
Fogler WE, Talmadge JE, Fidler IJ (1983) The activation of tumouricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome encapsulated immunomodulators. J Reticuloendothel Soc 33:165
Gisler RH, Schumann G, Sackmann W, Pericin, C, Tarcsay L, Dietrich FM (1982) A novel muramyl peptide, MTP-PE: profile of biological activities. In: Yamamura Y, Kotani S (eds) Immunomodulation by microbial products and related synthetic compounds. Excerpta Medica, Amsterdam Oxford Princeton p 167
Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ (1982) Isolation of tumouricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69:1189
Kleinermann E, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ (1983) Activation of tumouricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43:2010
Koff WC, Fidler IJ, Showalter SD, Chatzrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES (1984) Human monocytes activated by immunomodulators in liposomes lyse Herpes simplex virus infected but not normal cells. Science 224:1007
Lederer E (1982) Immunomodulation by muramyl dipeptides: recent developments. Clin Immunol Newsl 3 (13):83
Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersch EM (1983) The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol 130:1500
Mehta KH, Lopez-Berestein G, Hersch EM, Juliano RL (1982) Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32:155
Parant M (1979) Biological properties of a new synthetic adjuvant, muramyl dipeptide (MDP). Semin Immunopathol 2:101
Schoenfeld D (1981) The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrics 68:316
Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of tumouricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42:161
Sone S. Fidler IJ (1981) In vitro activation of tumouricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57:42
Sone S, Tsubura E (1982) Human alveolar macrophages: potentiation of their tumouricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol 129:1313
Sone S, Mutsuura S, Ogowara M, Tsubura E (1984) Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol 132:2105
Xu Z, Fidler IJ (1984) The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol Immunother 18:118
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brownbill, A.F., Braun, D.G., Dukor, P. et al. Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide. Cancer Immunol Immunother 20, 11–17 (1985). https://doi.org/10.1007/BF00199767
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199767